• IM/Hematology/Oncology

Arsen Osipov, MD is a medical oncologist and clinical-translational investigator in the Gastrointestinal Disease Research Group and Pancreas Cancer Research Group of the Samuel Oschin Cancer Center at Cedars-Sinai. Dr. Osipov was previously a resident physician and selected as Chief Resident at Cedars. He rejoined Cedars-Sinai as faculty after completing his training in medical oncology at Johns Hopkins, where he was also appointed Chief Clinical and Research Fellow. Dr. Osipov's research interests include understanding the biology of the tumor microenvironment and stroma of pancreas cancer, as well as developing novel immunotherapy-based treatment strategies for gastrointestinal malignancies with a focus on pancreatic cancer. Dr. Osipov integrates state-of-the-art multiplex imaging and analysis of tumor tissues to study the immune environment of pancreatic cancer and investigate new targets for immunotherapy sensitization, including focal adhesion kinase. Through this unique work, Dr. Osipov has developed multiple innovative neoadjuvant clinical trials in pancreatic cancer founded on translational preclinical laboratory science which utilize immunotherapy in combination with novel targeted approaches. Dr. Osipov focuses on a multidisciplinary approach for both his research and clinical endeavors, bringing together colleagues from hepatobiliary surgery, gastroenterology, radiation oncology, radiology and basic science to optimize scientific discovery and patient care. The goal of Dr. Osipov's research is to unlock the immense potential of immunotherapy in pancreatic cancer and thus advance treatment strategies and improve clinical outcomes for patients afflicted with this disease.

View NIH Biographical Sketch as a PDF

• MD: Virginia Commonwealth University School of Medicine, 2013
• Residency: Cedars-Sinai Medical Center, 2017
• Fellowship: Johns Hopkins University, School of Medicine, 2020

View CV as a PDF

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Gastrointestinal Oncology Center
• Pancreatic and Biliary Diseases
• Pancreatic Cancer

• Recipient of Linda Rubin Fellowship in Pancreas and GI Oncology Research Endowment, Johns Hopkins University, 2019 - 2020
• Chief Medical Oncology Fellow, Medical Oncology, Johns Hopkins University, School of Medicine, Baltimore, MD, 2019 - 2020
• ASCO Conquer Cancer Foundation, Young Investigator Award, 2019
• ASCO/AACR, Workshop on Methods in Clinical Cancer Research Workshop, 2018
• Chief Resident, Internal Medicine, Cedars-Sinai & Greater Los Angeles (GLA) Veterans Administration, Los Angeles, CA, 2016 - 2017

• Osipov A, Lim SJ, Popovic A, et al. Tumor Mutational Burden, Toxicity and Response of Immune Checkpoint Inhibitors (ICIs) Targeting PD(L)1, CTLA-4, and Combination: A Meta-Regression Analysis [published online ahead of print, 2020 Jun 25]. Clin Cancer Res. 2020;clincanres.0458.2020. doi:10.1158/1078 0432.CCR-20-0458
• Osipov A, Murphy A, Zheng L. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Adv Cancer Res. 2019;143:63 144. doi:10.1016/bs.acr.2019.03.002
• Osipov A, Naziri J, Hendifar A, et al. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J Gastrointest Oncol. 2016;7(2):239-247. doi:10.3978/j.issn.2078-6891.2015.109